NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $32,000 | -98.3% | 1,612 | -98.5% | 0.01% | -98.4% |
| Q4 2020 | $1,832,000 | +13.3% | 107,736 | +16.0% | 0.32% | +3.9% |
| Q3 2020 | $1,617,000 | +3.0% | 92,836 | +29.2% | 0.31% | -10.8% |
| Q2 2020 | $1,570,000 | +53.2% | 71,836 | +45.6% | 0.34% | +28.5% |
| Q1 2020 | $1,025,000 | +75.5% | 49,336 | +86.9% | 0.27% | +62.8% |
| Q4 2019 | $584,000 | +16.6% | 26,400 | -11.6% | 0.16% | -6.3% |
| Q3 2019 | $501,000 | +21.0% | 29,874 | +125.1% | 0.18% | +0.6% |
| Q2 2019 | $414,000 | +24.0% | 13,274 | +28.0% | 0.17% | +22.5% |
| Q1 2019 | $334,000 | +16.8% | 10,374 | +46.2% | 0.14% | -4.1% |
| Q4 2018 | $286,000 | +13.9% | 7,098 | +7.6% | 0.15% | +5.7% |
| Q3 2018 | $251,000 | – | 6,598 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |